OncoCyte (OCX) News Today $2.75 +0.20 (+7.84%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Critical Comparison: OncoCyte (NASDAQ:OCX) versus Oruka Therapeutics (NASDAQ:ORKA)November 15, 2024 | americanbankingnews.comOncoCyte Corp Reports Q3 2024 Earnings and Strategic UpdatesNovember 13, 2024 | markets.businessinsider.comOncoCyte’s Strategic Advances and Financial Prudence Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comOncoCyte Corporation (NASDAQ:OCX) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comOncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ...November 13, 2024 | uk.finance.yahoo.comOncoCyte Corporation (OCX) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comOncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.comNovember 12, 2024 | americanbankingnews.comWhat to Expect from OncoCyte's EarningsNovember 11, 2024 | benzinga.comOncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12November 6, 2024 | globenewswire.comOncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.comStockNews.com assumed coverage on shares of OncoCyte in a research note on Saturday. They issued a "sell" rating on the stock.November 2, 2024 | marketbeat.comOncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.comStockNews.com initiated coverage on shares of OncoCyte in a research report on Sunday. They issued a "sell" rating for the company.October 27, 2024 | marketbeat.comOncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los AngelesOctober 16, 2024 | globenewswire.comOncoCyte’s Strategic Shift and Market Potential Justify Buy RatingOctober 16, 2024 | markets.businessinsider.comInsider Buying Slows, but Not for 7 These BuyersOctober 13, 2024 | 247wallst.comOncoCyte Corp (OCX) Q2 2024 Earnings Call Highlights: Strategic Advances Amidst Financial ChallengesOctober 9, 2024 | finance.yahoo.comOncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical TrialOctober 8, 2024 | markets.businessinsider.comOncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical TrialOctober 8, 2024 | globenewswire.comBroadwood Partners, L.P. Purchases 1,315,339 Shares of OncoCyte Co. (NASDAQ:OCX) StockOctober 7, 2024 | insidertrades.comOncoCyte Secures Funding Through Private Share SaleOctober 4, 2024 | finance.yahoo.comOncocyte Signs Leading Transplant Centers in US and GermanyOctober 2, 2024 | globenewswire.comOncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesOctober 2, 2024 | globenewswire.comBTIG Sticks to Their Hold Rating for OncoCyte (OCX)September 24, 2024 | markets.businessinsider.comPRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics TechnologyAugust 20, 2024 | finance.yahoo.comOncoCyte Corporation: Oncocyte's VitaGraft Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series StudyAugust 15, 2024 | finanznachrichten.deOncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series StudyAugust 12, 2024 | finance.yahoo.comOncocyte's VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series StudyAugust 12, 2024 | globenewswire.comOncoCyte Corporation (NASDAQ:OCX) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | msn.comOCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024August 10, 2024 | msn.comOncocyte Announces Successful GraftAssure(TM) Beta Launch and Q2 2024 ResultsAugust 10, 2024 | stockhouse.comOncoCyte’s Growth Potential and Strategic Positioning Bolster Buy RatingAugust 9, 2024 | markets.businessinsider.comOncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 ResultsAugust 9, 2024 | markets.businessinsider.comOncocyte earnings preview: what Wall Street is expectingAugust 8, 2024 | markets.businessinsider.comOncocyte to Announce Second Quarter 2024 Financial Results on August 8August 1, 2024 | globenewswire.comOncoCyte’s (OCX) Stock Rises With New Diagnostic Product and Promising Partnership.July 24, 2024 | msn.comOncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership MoveJune 24, 2024 | globenewswire.comOncocyte Appoints Andrea James as Chief Financial OfficerJune 17, 2024 | globenewswire.comBreakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft StudyJune 3, 2024 | globenewswire.comFavorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of MedicineMay 30, 2024 | globenewswire.comOncoCyte’s Strategic Initiatives and Financial Health Garner Buy RatingMay 16, 2024 | markets.businessinsider.comOncoCyte Corporation: Oncocyte Reports First Quarter 2024 Financial ResultsMay 16, 2024 | finanznachrichten.deOncoCyte Corp (OCX) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...May 16, 2024 | finance.yahoo.com4 Analysts Assess OncoCyte: What You Need To KnowMay 16, 2024 | markets.businessinsider.comOncoCyte Corporation (NASDAQ:OCX) Q1 2024 Earnings Call TranscriptMay 16, 2024 | msn.comOncocyte Reports First Quarter 2024 Financial ResultsMay 15, 2024 | globenewswire.comOncoCyte Q1 2024 Earnings PreviewMay 14, 2024 | msn.comOncocyte to Announce First Quarter 2024 Financial ResultsMay 13, 2024 | finance.yahoo.comPRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics MarketplaceMay 7, 2024 | finance.yahoo.com3 Penny Stocks That Insiders Are Buying (OCX)May 7, 2024 | insidertrades.comStrong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial EfficiencyApril 24, 2024 | markets.businessinsider.comBuffett Grabs More of This Stock, Plus Other Notable Insider BuyingApril 22, 2024 | msn.com Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here OCX Media Mentions By Week OCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCX News Sentiment▼-0.310.45▲Average Medical News Sentiment OCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCX Articles This Week▼11▲OCX Articles Average Week Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Achilles Therapeutics News DBV Technologies News ImmuCell News DURECT News Aspira Women's Health News InflaRx News Instil Bio News MediWound News Adaptimmune Therapeutics News LifeVantage News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
